Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lung Diseases × zimberelimab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Uterine Cervical Neoplasms 8 Carcinoma, Non-Small-Cell Lung 8 Stomach Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 5 Triple Negative Breast Neoplasms 3 Recurrence 3 Pancreatic Neoplasms 3 Advanced Solid Tumors 3 Solid Tumor 2 Neoplasms 2 Neoplasm Metastasis 2 Melanoma 2 Lung Neoplasms 2 Esophageal Neoplasms 2 Cholangiocarcinoma 2 Carcinoma, Renal Cell 2 Adenocarcinoma Of Esophagus 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Urothelial Bladder Carcinoma 1 Urinary Bladder Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Thymoma 1 Solid Tumors 1 Solid Tumor, Unspecified, Adult 1 Sarcoma 1 Rectal Neoplasms 1 Prostatic Neoplasms, Castration-Resistant 1 Prostatic Neoplasms 1 Pharyngeal Neoplasms 1

Interventions

Carboplatin 14 Pemetrexed 7 Paclitaxel 5 Cisplatin 5 pembrolizumab 4 Nivolumab 4 osimertinib 3 zipalertinib 2 selpercatinib 2 pralsetinib 2 entinostat 2 durvalumab 2 atezolizumab 2 apatinib 2 One-Lung Ventilation 2 Ipilimumab 2 Erlotinib Hydrochloride 2 Bronchoscopy 2 Bevacizumab 2 130-nm albumin-bound paclitaxel 2 zimberelimab 1 toripalimab 1 taletrectinib 1 spartalizumab 1 sintilimab 1 sacituzumab govitecan 1 repotrectinib 1 patritumab 1 lorlatinib 1 ficlatuzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06431633 2025-04-10

ARIAN

Fundación GECP

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡